TA Repeat Polymorphism of the 5α-Reductase Gene and Breast Cancer

DOI: Published April 2000

Article Figures & Data

Download figure
Open in new tab
Download powerpoint
Fig. 1.
Representative DNA fragment analysis of three patients and one molecular weight standard run (last lane). The various TA length alleles are shown. The first patient is heterozygous (TA)₀/(TA)₉. Numbers below peaks, PCR product length in bp.
Download figure
Open in new tab
Download powerpoint
Fig. 2.
Distribution of TA genotypes in DNA from breast carcinomas and in DNA from leukocytes from females without breast cancer. As determined by the χ² test, the differences were not statistically significant (P = 0.15). (TA)₀, no TA repeats present; (TA)₉, nine TA repeats present in the 3′ untranslated region of the SRD5A2 gene.
Download figure
Open in new tab
Download powerpoint
Fig. 3.
Relationship between TA genotypes and breast tumor extract PSA concentrations. ——, mean value. The medians were 7.1 ng/g and 10.2 ng/g for (TA)₀ and (TA)₀/(TA)₉ or (TA)₉ genotypes, respectively; P = 0.041, as determined by the Mann-Whitney U test.
Download figure
Open in new tab
Download powerpoint
Fig. 4.
DFS (A) and OS (B) curves in breast cancer patients with TA₀ and (TA)₀/(TA)₉ or (TA)₉ genotypes, respectively. Vertical tick marks, the censored cases. Differences between genotypes were determined by log-rank tests.

Table 1

Associations of TA genotypes with features of breast cancer

^a χ² test.
^b Fisher’s exact test.
^c Bloom-Richardson grading system.
^d TNM system.
^e Cutoff point: 10 fmol/mg protein.
^f Cutoff point: 60 ng/g protein, equal to the 75th percentile of the distribution of PSA concentrations.

Table 2

Associations of TA genotypes with breast cancer survival

^a RR estimated from Cox proportional hazards regression model.
^b CI of the estimated RR.
^c Multivariate models were adjusted for lymph nodes status, tumor size, patient age, and ER and PR expression.